Quick Summary

Houttuynia cordata is a traditional Chinese medicinal herb reported to have anti-inflammatory, antiviral, antibacterial, immunomodulatory, and antioxidant properties. Research includes in vitro, animal, and clinical studies exploring its potential roles in respiratory infections such as mycoplasma pneumonia, viral pneumonia including COVID-19 and influenza, inflammatory conditions, and other health areas. It is frequently studied as part of multi-herb formulations and alongside conventional treatments. Despite promising preclinical results, high-quality human clinical trial data specifically assessing Houttuynia cordata are limited, and further rigorous research is needed.

What is it

Houttuynia cordata, commonly known as Houttuynia, is a perennial herb native to Southeast Asia. It has been used in traditional Chinese medicine (TCM) for centuries, primarily for its reported effects on respiratory and inflammatory conditions. The fresh or dried plant material is used in various forms including extracts, granules, and injections within polyherbal preparations.

Traditional Uses

  • Treatment of respiratory infections such as pneumonia and bronchitis
  • Management of inflammatory conditions
  • Antiviral and antibacterial support in traditional formulations
  • Adjunct to conventional therapies for lung and immune-related ailments

Active Compounds

Houttuynia cordata contains a variety of phytochemicals believed to contribute to its biological activity, including flavonoids, alkaloids, essential oils, and polysaccharides. These compounds have been studied mainly in preclinical settings for anti-inflammatory and antiviral effects.

Potential Benefits with Evidence Levels

  • Respiratory Infections and Immune Modulation in Humans (Moderate evidence): Clinical meta-analyses of TCM formulas containing Houttuynia, such as Lianhua Qingwen granules combined with azithromycin, show improved cure rates and reduced inflammatory markers in children with mycoplasma pneumoniae pneumonia (MPP). Combined TCM and Western medicine approaches may shorten symptom duration and enhance lung function in mild to moderate respiratory infections including COVID-19. However, the specific role of Houttuynia alone remains unclear.
  • Anti-inflammatory Effects (Preclinical – In Vitro): Laboratory studies demonstrate that Houttuynia cordata crude extracts can reduce pro-inflammatory cytokines such as IL-6, IL-8, IL-1β, and TNF-α in oral inflammatory cell models without cytotoxic effects.
  • Antiviral Potential (Preclinical and Clinical Context): Included in TCM formulations investigated for antiviral activities against influenza, coronaviruses, and other respiratory viruses. While natural product research suggests antiviral properties, direct high-quality clinical evidence of Houttuynia’s antiviral efficacy alone is insufficient.
  • Adjunct Therapy in Lung Conditions and Pneumonia (Moderate evidence): Systematic reviews indicate that TCM compounds including Houttuynia combined with antibiotics can improve clinical outcomes such as fever duration, cough disappearance, and reduce inflammatory biomarkers in pneumonia patients.

Side Effects

Combination therapies including Houttuynia-containing formulations generally report fewer adverse reactions compared to antibiotic-only treatments in clinical trials for pneumonia and respiratory infections. Specific safety data on Houttuynia cordata as a single agent are limited. Historical reviews note adverse reactions related to Houttuynia injections, which require monitoring. Experimental models have indicated potential embryotoxicity, though clinical relevance remains unclear. Oral formulations combined with standard therapies have not documented severe adverse effects in clinical trials.

Drug Interactions

There is no direct evidence of drug interactions specific to Houttuynia cordata. Clinical studies combining Houttuynia-containing traditional Chinese medicine with antibiotics report no increase in adverse events, suggesting compatibility. However, detailed interaction data are lacking, and caution is advised when combining with other medications.

Who Should Avoid It

  • Pregnant or breastfeeding women should avoid Houttuynia cordata due to preclinical evidence of potential embryotoxicity affecting critical signaling pathways in embryonic development.
  • Individuals with known allergies to components of Houttuynia or related botanical species should exercise caution.
  • People considering use of Houttuynia as a monotherapy should consult a healthcare professional given limited isolated safety data.

Evidence Limitations

  • Lack of high-quality, double-blind, placebo-controlled randomized clinical trials isolating Houttuynia cordata as a single agent.
  • Most clinical data are derived from combination TCM formulas containing multiple herbs, so effects cannot be attributed solely to Houttuynia.
  • Safety evidence primarily reflects combination therapies; isolated safety and drug interaction profiles remain poorly characterized.
  • Experimental embryotoxicity findings have not been confirmed in clinical human studies.
  • Variability in study designs, small sample sizes, and formulation differences complicate interpretation.
  • Further rigorous pharmacokinetic, mechanistic, and translational research is needed.

References

Last Reviewed

June 2024

Informational Disclaimer

This page is for informational purposes only and does not constitute medical advice. The safety and efficacy of Houttuynia cordata have not been fully established through rigorous clinical trials. Always consult a qualified healthcare professional before starting any new herbal supplement or therapy, especially if you are pregnant, breastfeeding, have existing health conditions, or are taking other medications.